ClinicalTrials.gg
CompletedNCT00175825Updated Oct 2, 2018Results posted

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

A Phase 2 interventional study of Placebo and Brivaracetam in Epilepsy, sponsored by UCB Pharma. Completed at 42 sites in 4 countries. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
10th of 34
210 · median 94
Started
2005
with 3 others
Phase 2
6 of 34
none open now
Registered
2nd of 34
by date
Lead sponsor
13 of 34
UCB Pharma

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 10th largest by enrollment, is one of 4 that started in 2005, is one of 6 in phase 2, and was the 2nd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy: partial onset seizures
  • brivaracetam
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male/female from 16 to 65 years
  • Well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
  • History of partial onset seizures
  • Subjects having at least 4 partial onset seizures during the 4-week Baseline Period and at least 2 partial onset seizures during the 3 months prior to Visit 1
  • Subjects taking 1 or 2 concomitant Antiepileptic drugs (AED(s)) that have been at a stable dose.

Exclusion criteria

Exclusion Criteria:

  • Seizure type IA non-motor as only seizure type
  • Seizures occurring only in clusters
  • Status epilepticus during the last 2 years before Visit 1
  • History of cerebrovascular accident (CVA)
  • Presence of any sign suggesting rapidly progressing brain disorder or brain tumor
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching Placebo tablets administered twice a day

    Other: Placebo

  • Experimental
    Brivaracetam 5 mg/day

    Brivaracetam 5 mg/day, 2.5 mg administered twice a day

    Drug: Brivaracetam

  • Experimental
    Brivaracetam 20 mg/day

    Brivaracetam 20 mg/day, 10 mg administered twice a day

    Drug: Brivaracetam

  • Experimental
    Brivaracetam 50 mg/day

    Brivaracetam 50 mg/day, 25 mg administered twice a day

    Drug: Brivaracetam

Interventions

  • OtherPlacebo

    Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period

  • Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period

    Also known as: Briviact

06

What researchers measure

Primary outcomes

  1. Partial Onset Seizure Frequency Per Week During the 7-week Treatment Period

    Calculated as 7-day partial onset seizure frequency.

    Time frame: During the 7-week Treatment Period

Secondary outcomes

  1. Percentage Change From Baseline in Partial Onset Seizure Frequency Per Week (Type I) Over the 7-week Treatment Period

    Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.

    Time frame: Baseline, during the 7-week Treatment Period

  2. Seizure Frequency Per Week for All Seizures (Types I +II +III) Over the Treatment Period

    Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or nonconvulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 7-day period.

    Time frame: During the 7-week Treatment Period

  3. Absolute Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Over the Treatment Period

    Calculated as 7-day Partial Onset Seizures (Type I) frequency during the 7-week Treatment Period 7-day seizure frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.

    Time frame: During the 7-week Treatment Period

  4. Absolute Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period

    Calculated as 7-day seizure frequency during the 7-week Treatment Period 7-day seizure (Types I + II + III) frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.

    Time frame: During the 7-week Treatment Period

  5. Percentage Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period

    Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.

    Time frame: During the 7-week Treatment Period

  6. Responder Rate in Partial Onset Seizures (Type I) Over the Treatment Period

    A responder was defined as a subject with a \>= 50 % reduction in seizure frequency per week from the Baseline Period to the end of the Treatment Period.

    Time frame: During the 7-week Treatment Period

  7. Percentage of Subjects With Categorized Response to the Treatment in Partial Onset Seizures (Type I) Over the Treatment Period

    Categories of percentage reductions in seizures from baseline were as following: \< -25 %; -25 % to \<25 %; 25 % to \<75 %; 75 % to \<100 %; 100 %.

    Time frame: During the 7-week Treatment Period

  8. Percentage of Subjects Who Are Seizure Free During the 7-week Treatment Period

    A subject was considered seizure free, if no seizure was reported during the 7-week Treatment Period.

    Time frame: During the 7-week Treatment Period

  9. Number of Seizure-free Days Per 4 Weeks

    A day was considered seizure-free, if no seizure was reported during 24 hours.

    Time frame: Baseline, during the 7-week Treatment Period

  10. Time to Nth (n= 1, 5, 10) Seizure During the 7-week Treatment Period

    Number of days to first, fifth, and tenth seizure after baseline.

    Time frame: During the 7-week Treatment Period

07

Results

Posted Aug 22, 2018

Participant flow

The study started to enroll patients in November 2005 and concluded in June 2006.

Participant flow — Overall Study
MilestonePlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Started54505252
Completed49465151
Not completed5411
Withdrew: Adverse event3211
Withdrew: Lost to follow-up1200
Withdrew: Withdrawal by subject1000

Outcome measures

SecondaryPercentage Change From Baseline in Partial Onset Seizure Frequency Per Week (Type I) Over the 7-week Treatment Period

Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.

Time frame:
Baseline, during the 7-week Treatment Period
Reported as:
Median · percentage of change
Percentage Change From Baseline in Partial Onset Seizure Frequency Per Week (Type I) Over the 7-week Treatment Period
percentage of changePlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Percentage Change From Baseline in Partial Onset Seizure Frequency Per Week (Type I) Over the 7-week Treatment Period-21.7 (-42.99 to 12.04)-29.91 (-53.33 to -3.83)-42.56 (-67.92 to 0.44)-53.04 (-69.33 to -19.56)
SecondarySeizure Frequency Per Week for All Seizures (Types I +II +III) Over the Treatment Period

Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or nonconvulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 7-day period.

Time frame:
During the 7-week Treatment Period
Reported as:
Median · seizures per week
Seizure Frequency Per Week for All Seizures (Types I +II +III) Over the Treatment Period
seizures per weekPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Baseline2.23 (1.30 to 4.22)2.21 (1.38 to 5.00)2.50 (1.50 to 6.06)1.99 (1.36 to 3.97)
Treatment1.81 (0.88 to 3.50)1.61 (0.75 to 4.34)1.70 (0.59 to 3.97)0.92 (0.69 to 2.05)
SecondaryAbsolute Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Over the Treatment Period

Calculated as 7-day Partial Onset Seizures (Type I) frequency during the 7-week Treatment Period 7-day seizure frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.

Time frame:
During the 7-week Treatment Period
Reported as:
Median · seizures per week
Absolute Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Over the Treatment Period
seizures per weekPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Absolute Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) Over the Treatment Period-0.37 (-1.18 to 0.19)-0.66 (-1.19 to -0.07)-0.84 (-2.21 to -0.08)-0.92 (-2.44 to -0.24)
SecondaryAbsolute Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period

Calculated as 7-day seizure frequency during the 7-week Treatment Period 7-day seizure (Types I + II + III) frequency during the Baseline Period. A negative value from Baseline indicates a decrease in partial seizure frequency from Baseline.

Time frame:
During the 7-week Treatment Period
Reported as:
Median · seizures per week
Absolute Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period
seizures per weekPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Absolute Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period-0.40 (-1.18 to 0.19)-0.66 (-1.19 to -0.07)-0.80 (-2.21 to -0.08)-0.92 (-2.44 to -0.37)
SecondaryPercentage Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period

Calculated as 7-day seizure frequency during the 7-week Treatment Period - 7-day seizure frequency during the Baseline Period, divided by the 7-day seizure frequency during the Baseline Period with this quantity multiplied by 100. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline.

Time frame:
During the 7-week Treatment Period
Reported as:
Median · percentage of change
Percentage Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period
percentage of changePlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Percentage Change From Baseline in Seizure Frequency Per Week for All Seizures (Types I + II + III) Over the Treatment Period-24.35 (-43.61 to 12.00)-29.91 (-53.33 to -3.83)-41.57 (-65.31 to 0.44)-53.05 (-69.33 to -22.82)
SecondaryResponder Rate in Partial Onset Seizures (Type I) Over the Treatment Period

A responder was defined as a subject with a \>= 50 % reduction in seizure frequency per week from the Baseline Period to the end of the Treatment Period.

Time frame:
During the 7-week Treatment Period
Reported as:
Number · percentage of participants
Responder Rate in Partial Onset Seizures (Type I) Over the Treatment Period
percentage of participantsPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Responder Rate in Partial Onset Seizures (Type I) Over the Treatment Period16.732.044.255.8
SecondaryPercentage of Subjects With Categorized Response to the Treatment in Partial Onset Seizures (Type I) Over the Treatment Period

Categories of percentage reductions in seizures from baseline were as following: \< -25 %; -25 % to \<25 %; 25 % to \<75 %; 75 % to \<100 %; 100 %.

Time frame:
During the 7-week Treatment Period
Reported as:
Number · percentage of participants
Percentage of Subjects With Categorized Response to the Treatment in Partial Onset Seizures (Type I) Over the Treatment Period
percentage of participantsPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
< -25%18.58.09.613.5
-25% to <25%35.238.030.813.5
25% to <75%40.742.040.455.8
75% to <100%1.94.011.59.6
100%3.78.07.77.7
SecondaryPercentage of Subjects Who Are Seizure Free During the 7-week Treatment Period

A subject was considered seizure free, if no seizure was reported during the 7-week Treatment Period.

Time frame:
During the 7-week Treatment Period
Reported as:
Number · percentage of participants
Percentage of Subjects Who Are Seizure Free During the 7-week Treatment Period
percentage of participantsPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Completed the Period1.98.07.75.8
Discontinued from the Period1.9000
SecondaryNumber of Seizure-free Days Per 4 Weeks

A day was considered seizure-free, if no seizure was reported during 24 hours.

Time frame:
Baseline, during the 7-week Treatment Period
Reported as:
Median · Days/4 Weeks
Number of Seizure-free Days Per 4 Weeks
Days/4 WeeksPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Number of Seizure-free Days Per 4 Weeks22.66 (16.57 to 24.57)22.86 (15.43 to 25.14)22.84 (18.57 to 25.71)24.65 (21.14 to 25.86)
SecondaryTime to Nth (n= 1, 5, 10) Seizure During the 7-week Treatment Period

Number of days to first, fifth, and tenth seizure after baseline.

Time frame:
During the 7-week Treatment Period
Reported as:
Median · days
Time to Nth (n= 1, 5, 10) Seizure During the 7-week Treatment Period
daysPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Number of days to first seizure after baseline4.0 (3.0 to 6.0)4.0 (3.0 to 7.0)4.5 (2.0 to 8.0)7.0 (4.0 to 13.0)
Number of days to fifth seizure after baseline17.0 (13.0 to 22.0)20.0 (17.0 to 27.0)18.5 (14.0 to 29.0)32.5 (23.0 to 42.0)
Number of days to tenth seizure after baseline32.0 (23.0 to 45.0)38.0 (27.0 to NA)39.0 (23.0 to NA)57.0 (49.0 to NA)
PrimaryPartial Onset Seizure Frequency Per Week During the 7-week Treatment Period

Calculated as 7-day partial onset seizure frequency.

Time frame:
During the 7-week Treatment Period
Reported as:
Median · Seizures per week
Partial Onset Seizure Frequency Per Week During the 7-week Treatment Period
Seizures per weekPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
Partial Onset Seizure Frequency Per Week During the 7-week Treatment Period1.81 (0.88 to 3.50)1.61 (0.75 to 4.34)1.55 (0.57 to 3.83)0.92 (0.69 to 2.05)
Statistical analysis
  • Placebo vs Brivaracetam 5 mg/Day · ANCOVA · p = =0.240 · Percent reduction over placebo: 9.8 · 95% CI -7.2 to 24.0
  • Placebo vs Brivaracetam 20 mg/Day · ANCOVA · p = =0.062 · Percent reduction over placebo: 14.9 · 95% CI -0.8 to 28.2
  • Placebo vs Brivaracetam 50 mg/Day · ANCOVA · p = =0.004 · Percent reduction over placebo: 22.1 · 95% CI 7.6 to 34.3

Adverse events

Collected over Adverse events were collected from Baseline until Safety Visit (up to 3 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/54 (0%)0/54 (0%)15/54 (27.8%)
Brivaracetam 5 mg/Day0/50 (0%)0/50 (0%)13/50 (26%)
Brivaracetam 20 mg/Day0/52 (0%)1/52 (1.9%)8/52 (15.4%)
Brivaracetam 50 mg/Day0/52 (0%)0/52 (0%)10/52 (19.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
NeurotoxicityNervous system disorders0/540/501/520/52
Most frequent other events
Most frequent other events
EventPlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/Day
NeutropeniaBlood and lymphatic system disorders1/544/502/521/52
InfluenzaInfections and infestations4/544/500/521/52
HeadacheNervous system disorders4/544/502/521/52
DizzinessNervous system disorders3/541/500/524/52
SomnolenceNervous system disorders4/541/503/523/52
FatigueGeneral disorders2/540/502/523/52

Baseline characteristics

Baseline Characteristics refer to the Intention-to-Treat (ITT) Set.

Age, Categorical
Age, Categorical(Participants)PlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayTotal Title
<=18 years341513
Between 18 and 65 years51465047194
>=65 years00101
Age, Continuous
Age, Continuous(years)PlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayTotal Title
Mean33.59 ± 11.2632.72 ± 12.1635.31 ± 13.6630.92 ± 11.5733.15 ± 12.20
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBrivaracetam 5 mg/DayBrivaracetam 20 mg/DayBrivaracetam 50 mg/DayTotal Title
Female3020242498
Male24302828110
08

Study locations

42 sites
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Fresno, California, United States
  • Bradenton, Florida, United States
  • Jacksonville, Florida, United States
  • Chicago, Illinois, United States
  • Paducah, Kentucky, United States
  • Ruston, Louisiana, United States
  • Bethesda, Maryland, United States
  • Burlington, Massachusetts, United States
  • Grand Rapids, Michigan, United States
  • Rochester, Minnesota, United States
  • Tupelo, Mississippi, United States
  • Chesterfield, Missouri, United States
  • Great Falls, Montana, United States
  • Englewood Cliffs, New Jersey, United States
  • Toms River, New Jersey, United States
  • New York, New York, United States
  • Wilmington, North Carolina, United States
  • Columbus, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Woonsocket, Rhode Island, United States
  • Greenville, South Carolina, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Florianopolis, Brazil
  • Salvador, Brazil
  • Sao Paulo, Brazil
  • Bangalore, India
  • Hyderabad, India
  • Lucknow, India
  • Parel Mumbai, India
  • Trivandrum, India
  • Aguascalientes, Mexico
  • Chichuahua, Mexico
  • Chihuahua, Mexico
  • Guadalajara, Mexico
  • Monterrey, Mexico
  • San Luis Potosi, Mexico
  • Valle Oriente Garza Garcia, Mexico
  • Zapopan, Mexico
09

References and documents

Publications

  • Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, Borghs S, Kwan P. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016 Jul;57(7):1139-51. doi: 10.1111/epi.13416. Epub 2016 Jun 6. PubMed 27265725 ↗
  • Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2022 Mar 14;3(3):CD011501. doi: 10.1002/14651858.CD011501.pub3. PubMed 35285519 ↗
  • Brandt C, Klein P, Badalamenti V, Gasalla T, Whitesides J. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis. Epilepsy Behav. 2020 Feb;103(Pt A):106864. doi: 10.1016/j.yebeh.2019.106864. Epub 2020 Jan 12. PubMed 31937513 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2005 to primary completion in Jun 2006, 7 months.

Results were first posted in Aug 2018, 12 years 1 month after primary completion.

Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 7 months is below that.

Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
StartActual
Nov 7, 2005
Primary completionActual
Jun 29, 2006
CompletionActual
Jun 29, 2006
Results first posted
Aug 22, 2018
Last update
Oct 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00175825
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Nov 7, 2005
Primary completion
Jun 29, 2006
Completion
Jun 29, 2006
Results posted
Aug 22, 2018
Last update
Oct 2, 2018

Study contacts

UCB Cares
study director · +1 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion